| Identification | Back Directory | [Name]
1H-Benzotriazole-7-carboxylic acid, 1-methyl-5-(2'-methyl[1,1'-biphenyl]-4-yl)- | [CAS]
1623416-31-8 | [Synonyms]
AG-636
1H-Benzotriazole-7-carboxylic acid, 1-methyl-5-(2'-methyl[1,1'-biphenyl]-4-yl)-
1-Methyl-5-(2'-methyl-[1,1'-biphenyl]-4-yl)-1H-benzo[d][1,2,3]triazole-7-carboxylic acid
inhibit,oral,AG 636,AG-636,reversible,DHODH,anticancer,AG636,Inhibitor,Dihydroorotate Dehydrogenase,DNA/RNA Synthesis | [Molecular Formula]
C21H17N3O2 | [MDL Number]
MFCD33023454 | [MOL File]
1623416-31-8.mol | [Molecular Weight]
343.38 |
| Chemical Properties | Back Directory | [Boiling point ]
619.3±43.0 °C(Predicted) | [density ]
1.27±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 31.25 mg/mL (91.01 mM; Need ultrasonic) | [form ]
A solid | [pka]
2.73±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
AG-636 is a potent, reversible, selective and orally active dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 17 nM. AG-636 has strong anticancer effects[1]. | [in vivo]
AG-636 (10-100 mg/kg ; oral gavage; twice daily; for 14 days) treatment results in robust tumor growth inhibition in the OCILY19 DLBCL tumor xenograft model[1]. | Animal Model: | Transgenic female 6-8-week-old CB17/Icr-Prkdcscid/IcrIcoCrl (CB17 SCID) mice injected with OCILY19 cells[1] | | Dosage: | 10 mg/kg, 30 mg/kg, or 100 mg/kg
| | Administration: | Oral gavage; twice daily; for 14 days | | Result: | Resulted in robust tumor growth inhibition in xenograft lymphoma tumor models. |
| [References]
[1] Gabrielle McDonald, et al. Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase. Mol Cancer Ther. 2020 Dec;19(12):2502-2515. DOI:10.1158/1535-7163.MCT-20-0550 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|